New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
First-in-human study initiations include Boundless Bio’s second asset, and an ADC from Tubulis.